{"id":499061,"date":"2020-07-28T16:14:01","date_gmt":"2020-07-28T16:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499061"},"modified":"2020-07-28T16:14:01","modified_gmt":"2020-07-28T16:14:01","slug":"castrateresistant-prostate-cancer-crpc-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/castrateresistant-prostate-cancer-crpc-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_499061.html","title":{"rendered":"Castrate-resistant Prostate Cancer (CRPC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Castrate-resistant Prostate Cancer (CRPC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Castrate-resistant Prostate Cancer (CRPC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Castrate-resistant Prostate Cancer (CRPC) -Market Insights, Epidemiology and Market Forecast &#8211; 2030&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight has introduced a new&nbsp;<strong>Market Insights<\/strong>,&nbsp;<strong>Epidemiology, and Market Forecast<\/strong>&nbsp;Report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/castrate-resistant-prostate-cancer-market\">&#8220;<strong>Castrate-Resistant Prostate Cancer &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/strong>&#8220;<\/a> to its portfolio.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &lsquo;<strong>Castrate-resistant Prostate Cancer (CRPC) -Market Insights, Epidemiology and Market Forecast &#8211; 2030<\/strong>&rsquo; report delivers an in-depth understanding of the CRPC, historical and forecasted epidemiology as well as the CRPC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The therapeutic market of CRPC in seven major markets was&nbsp;<strong>USD 6,160 million<\/strong>&nbsp;in 2017 which is expected to increase during study period (2017&ndash;2030).<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>The total cases of CRPC in the 7MM were found to be 265,891 in 2017 which is expected to grow during the study period, i.e., 2017&ndash;2030.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>The total prevalent cases of prostate cancer in the 7MM were observed to be <strong>6,742,385 <\/strong>cases in 2017Among patients, about 40% of them have mild IBS, 35% suffer from moderate IBS, and 25% from severe IBS,<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/castrate-resistant-prostate-cancer-market\">Request for Sample Pages: https:\/\/www.delveinsight.com\/sample-request\/castrate-resistant-prostate-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Report<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Castrate-resistant Prostate Cancer (CRPC) market report covers a descriptive overview and comprehensive insight of the Castrate-resistant Prostate Cancer (CRPC) epidemiology and Castrate-resistant Prostate Cancer (CRPC) market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>Castrate-resistant Prostate Cancer (CRPC) market report provides insights on the current and emerging therapies.&nbsp;<\/li>\n<li>Castrate-resistant Prostate Cancer (CRPC) market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/li>\n<li>Castrate-resistant Prostate Cancer (CRPC) market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Castrate-resistant Prostate Cancer (CRPC) market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men.&nbsp;This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm.<\/p>\n<p style=\"text-align: justify;\">According to the Cancer Treatment Centres of America (CTCA), more than 99% of&nbsp;prostate cancers&nbsp;are&nbsp;adenocarcinomas, which develop in the gland cells.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The exact cause of prostate cancer is unknown. However, several things can increase the risk of developing this condition like age, family history, diet, high testosterone level, genome changes, and race.<\/p>\n<p style=\"text-align: justify;\">Many patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE),prostate ultrasound, prostate MRI,prostate Mp-MRI.<\/p>\n<p style=\"text-align: justify;\">Treatment strategies of prostate cancers depend on the stage and progression of cancer. For localized or locally advanced prostate cancer active surveillance, surgery, and radiation therapy is the three major treatment options.<\/p>\n<p style=\"text-align: justify;\">Besides, this other treatment options for prostate cancers include chemotherapy, hormone therapy, and immunotherapy. Hormonal therapy has been a mainstay in the treatment of advanced prostate cancer.<\/p>\n<p style=\"text-align: justify;\">However, many prostate cancers ultimately fail to respond to androgen deprivation therapy (ADT) and are termed castrate-resistant prostate cancer (CRPC).<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/castrate-resistant-prostate-cancer-market\">Request for Sample Pages: https:\/\/www.delveinsight.com\/sample-request\/castrate-resistant-prostate-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>According to the analysis, it was estimated that prostate cancer is more prevalent in people of age between 65&ndash;74 years followed by 55&ndash;64 years and 75&ndash;84 years.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Drugs covered in the report are:-<\/strong><\/p>\n<p style=\"text-align: justify;\">There are several key players robustly involved in developing potential products such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Lynparza<\/li>\n<li>Rucaparib<\/li>\n<li>Opdivo<\/li>\n<li>Niraparib<\/li>\n<li>Ipatasertib<\/li>\n<li>HC-1119<\/li>\n<li>177Lu-PSMA-617<\/li>\n<li>Seviteronel<\/li>\n<li>Capivasertib<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Players covered in the report are:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AstraZeneca\/ Merck Sharp &amp; Dohme<\/li>\n<li>Clovis Oncology<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Janssen Research &amp; Development<\/li>\n<li>Hoffmann-La Roche<\/li>\n<li>Novartis<\/li>\n<li>Innocrin Pharmaceutical<\/li>\n<li>AstraZeneca<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/castrate-resistant-prostate-cancer-market\">Request for Sample Pages: https:\/\/www.delveinsight.com\/sample-request\/castrate-resistant-prostate-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Reasons to buy<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report will help in developing business strategies by understanding trends shaping and driving the CRPC market.<\/li>\n<li>To understand the future market competition in the CRPC market and Insightful review of the key market drivers and barriers.<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for CRPC in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.<\/li>\n<li>Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for CRPC market.<\/li>\n<li>To understand the future market competition in the CRPC market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><strong>Table of Contents<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of CRPC<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. SWOT Analysis of CRPC<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. CRPC: Market Overview at a Glance<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5. CRPC: Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p style=\"text-align: justify;\">5.1.1. Signs and Symptoms of Prostate Cancer<\/p>\n<p style=\"text-align: justify;\">5.1.2. Risk Factors and Causes of Prostate Cancer<\/p>\n<p style=\"text-align: justify;\">5.1.3. Pathophysiology of Prostate Cancer<\/p>\n<p style=\"text-align: justify;\">5.1.4. Prostate Neoplasia<\/p>\n<p style=\"text-align: justify;\">5.1.5. Genetics of Prostate Cancer<\/p>\n<p style=\"text-align: justify;\"><strong>6. Diagnosis of Prostate Cancer<\/strong><\/p>\n<p style=\"text-align: justify;\">6.1. Screening Tests for Prostate Cancer<\/p>\n<p style=\"text-align: justify;\">6.2. Tests to Diagnose Prostate Cancer<\/p>\n<p style=\"text-align: justify;\">6.3. Stages and Grades of Prostate Cancer<\/p>\n<p style=\"text-align: justify;\"><strong>7. Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\">7.1. Key Findings<\/p>\n<p style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.3. Total Non-metastatic and Metastatic Cases of CRPC in the 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.4. Total Treated cases of Non-metastatic CRPC Patients in the 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.5. Total Treated Cases of Metastatic CRPC Patients in the 7MM<\/p>\n<p style=\"text-align: justify;\">7.4. The United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.4.1. Total Diagnosed Cases of Prostate Cancer in the United States<\/p>\n<p style=\"text-align: justify;\">7.4.2. Age-specific Cases of Prostate Cancer in the United States<\/p>\n<p style=\"text-align: justify;\">7.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States<\/p>\n<p style=\"text-align: justify;\">7.4.4. Total Non-metastatic and Metastatic Cases of CRPC in the United States<\/p>\n<p style=\"text-align: justify;\">7.4.5. Total Treated cases of Non-metastatic CRPC Patients in the United States<\/p>\n<p style=\"text-align: justify;\">7.4.6. Total Treated Cases of Metastatic CRPC Patients in the United States<\/p>\n<p style=\"text-align: justify;\"><strong>8. EU-5 Country-wise Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">8.1. Germany<\/p>\n<p style=\"text-align: justify;\">8.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany<\/p>\n<p style=\"text-align: justify;\">8.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany<\/p>\n<p style=\"text-align: justify;\">8.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany<\/p>\n<p style=\"text-align: justify;\">8.1.4. Total Non-metastatic and Metastatic Cases of CRPC in Germany<\/p>\n<p style=\"text-align: justify;\">8.1.5. Total Treated cases of Non-metastatic CRPC Patients in Germany<\/p>\n<p style=\"text-align: justify;\">8.1.6. Total Treated Cases of Metastatic CRPC Patients in Germany<\/p>\n<p style=\"text-align: justify;\">8.2. France<\/p>\n<p style=\"text-align: justify;\">8.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France<\/p>\n<p style=\"text-align: justify;\">8.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France<\/p>\n<p style=\"text-align: justify;\">8.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France<\/p>\n<p style=\"text-align: justify;\">8.2.4. Total Non-metastatic and Metastatic Cases of CRPC in France<\/p>\n<p style=\"text-align: justify;\">8.2.5. Total Treated cases of Non-metastatic CRPC Patients in France<\/p>\n<p style=\"text-align: justify;\">8.2.6. Total Treated Cases of Metastatic CRPC Patients in France<\/p>\n<p style=\"text-align: justify;\">8.3. Italy<\/p>\n<p style=\"text-align: justify;\">8.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy<\/p>\n<p style=\"text-align: justify;\">8.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy<\/p>\n<p style=\"text-align: justify;\">8.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy<\/p>\n<p style=\"text-align: justify;\">8.3.4. Total Non-metastatic and Metastatic Cases of CRPC in Italy<\/p>\n<p style=\"text-align: justify;\">8.3.5. Total Treated cases of Non-metastatic CRPC Patients in Italy<\/p>\n<p style=\"text-align: justify;\">8.3.6. Total Treated Cases of Metastatic CRPC Patients in Italy<\/p>\n<p style=\"text-align: justify;\">8.4. Spain<\/p>\n<p style=\"text-align: justify;\">8.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain<\/p>\n<p style=\"text-align: justify;\">8.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain<\/p>\n<p style=\"text-align: justify;\">8.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain<\/p>\n<p style=\"text-align: justify;\">8.4.4. Total Non-metastatic and Metastatic Cases of CRPC in Spain<\/p>\n<p style=\"text-align: justify;\">8.4.5. Total Treated cases of Non-metastatic CRPC Patients in Spain<\/p>\n<p style=\"text-align: justify;\">8.4.6. Total Treated Cases of Metastatic CRPC Patients in Spain<\/p>\n<p style=\"text-align: justify;\">8.5. United Kingdom<\/p>\n<p style=\"text-align: justify;\">8.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">8.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">8.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">8.5.4. Total Non-metastatic and Metastatic Cases of CRPC in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">8.5.5. Total Treated cases of Non-metastatic CRPC Patients in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">8.5.6. Total Treated Cases of Metastatic CRPC Patients in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">8.6. Japan<\/p>\n<p style=\"text-align: justify;\">8.6.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan<\/p>\n<p style=\"text-align: justify;\">8.6.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan<\/p>\n<p style=\"text-align: justify;\">8.6.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan<\/p>\n<p style=\"text-align: justify;\">8.6.4. Total Non-metastatic and Metastatic Cases of CRPC in Japan<\/p>\n<p style=\"text-align: justify;\">8.6.5. Total Treated cases of Non-metastatic CRPC Patients in Japan<\/p>\n<p style=\"text-align: justify;\">8.6.6. Total Treated Cases of Metastatic CRPC Patients in Japan<\/p>\n<p style=\"text-align: justify;\"><strong>9. Current Treatment Practices: Prostate Cancer<\/strong><\/p>\n<p style=\"text-align: justify;\">9.1. Treatment Algorithm of Prostate Cancer<\/p>\n<p style=\"text-align: justify;\">9.2. Observation or Active Surveillance<\/p>\n<p style=\"text-align: justify;\">9.3. Surgery<\/p>\n<p style=\"text-align: justify;\">9.3.1. Open or Laparoscopic Radical Prostatectomy<\/p>\n<p style=\"text-align: justify;\">9.3.2. Risks of Prostate Surgery<\/p>\n<p style=\"text-align: justify;\">9.4. Radiation Therapy<\/p>\n<p style=\"text-align: justify;\">9.4.1. Types of Radiation Therapy<\/p>\n<p style=\"text-align: justify;\">9.5. Hormone Therapy<\/p>\n<p style=\"text-align: justify;\">9.5.1. Types of Hormone Therapy<\/p>\n<p style=\"text-align: justify;\">9.6. Immunotherapy<\/p>\n<p style=\"text-align: justify;\">9.6.1. Vaccine<\/p>\n<p style=\"text-align: justify;\">9.6.2. Immune checkpoint inhibitors<\/p>\n<p style=\"text-align: justify;\">9.7. Chemotherapy<\/p>\n<p style=\"text-align: justify;\"><strong>10. Guideline of Prostate Cancer<\/strong><\/p>\n<p style=\"text-align: justify;\">10.1. The European Association of Urology (EAU) Guideline for Management of Prostate Cancer: 2020<\/p>\n<p style=\"text-align: justify;\">10.2. The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer: 2019<\/p>\n<p style=\"text-align: justify;\">10.2.1. Screening Guidelines<\/p>\n<p style=\"text-align: justify;\">10.2.2. Genetic Testing<\/p>\n<p style=\"text-align: justify;\">10.2.3. Bone Scan for Diagnosis of Metastatic Disease<\/p>\n<p style=\"text-align: justify;\">10.2.4. Castration-Resistant Prostate Cancer (CRPC)<\/p>\n<p style=\"text-align: justify;\">10.3. Japanese Urological Association Clinical Practice Guideline for Prostate Cancer<\/p>\n<p style=\"text-align: justify;\"><strong>11. Unmet Needs of CRPC<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Marketed Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p style=\"text-align: justify;\">12.2. Xofigo (radium Ra 223 dichloride): Bayer Health Care<\/p>\n<p style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p style=\"text-align: justify;\">12.2.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">12.2.3. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.2.4. Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">12.2.5. Ongoing Current Pipeline Activity<\/p>\n<p style=\"text-align: justify;\">12.3. Xtandi (Enzalutamide): Astellas Pharma<\/p>\n<p style=\"text-align: justify;\">12.3.1. Product Description<\/p>\n<p style=\"text-align: justify;\">12.3.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">12.3.3. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.3.4. Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">12.3.5. Ongoing Current Pipeline Activity<\/p>\n<p style=\"text-align: justify;\">12.4. Erleada (apalutamide): Janssen Pharmaceutical<\/p>\n<p style=\"text-align: justify;\">12.4.1. Product Description<\/p>\n<p style=\"text-align: justify;\">12.4.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">12.4.3. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.4.4. Pivotal Clinical Trials<\/p>\n<p style=\"text-align: justify;\">12.4.5. Ongoing Current Pipeline Activity<\/p>\n<p style=\"text-align: justify;\">12.5. Jevtana (Cabazitaxel): Sanofi<\/p>\n<p style=\"text-align: justify;\">12.5.1. Product Description<\/p>\n<p style=\"text-align: justify;\">12.5.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">12.5.3. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.5.4. Pivotal Clinical Trials<\/p>\n<p style=\"text-align: justify;\">12.5.5. Ongoing Current Pipeline Activity<\/p>\n<p style=\"text-align: justify;\">12.6. Nubeqa (Darolutamide\/ODM-201): Bayer HealthCare\/Orion Corporation<\/p>\n<p style=\"text-align: justify;\">12.6.1. Product Description<\/p>\n<p style=\"text-align: justify;\">12.6.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">12.6.3. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.6.4. Pivotal Clinical Trials<\/p>\n<p style=\"text-align: justify;\">12.6.5. Ongoing Current Pipeline Activity<\/p>\n<p style=\"text-align: justify;\"><strong>13. Emerging Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\">13.1. Lynparza (Olaparib): AstraZeneca\/ Merck Sharp &amp; Dohme<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.1.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.2. Opdivo (nivolumab): Bristol-Myers Squibb<\/p>\n<p style=\"text-align: justify;\">13.2.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.2.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.2.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.3. 177Lu-PSMA-617: Novartis<\/p>\n<p style=\"text-align: justify;\">13.3.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.3.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.3.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.4. HC-1119: Hinova Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">13.4.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.4.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.4.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.5. Seviteronel (VT-464): Innocrin Pharmaceutical<\/p>\n<p style=\"text-align: justify;\">13.5.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.5.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.5.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.6. ODM-208: Orion Pharma<\/p>\n<p style=\"text-align: justify;\">13.6.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.6.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.6.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.7. Sacituzumab Govitecan (IMMU-132): Immunomedics<\/p>\n<p style=\"text-align: justify;\">13.7.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.7.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.8. Keytruda (Pembrolizumab\/MK-3475): Merck Sharp &amp; Dohme<\/p>\n<p style=\"text-align: justify;\">13.8.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.8.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.8.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.9. Ipatasertib (RG7440): Hoffmann-La Roche<\/p>\n<p style=\"text-align: justify;\">13.9.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.9.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.9.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.10. Talazoparib: Pfizer\/Astellas Pharma<\/p>\n<p style=\"text-align: justify;\">13.10.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.10.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.10.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.11. Capivasertib (AZD5363): AstraZeneca<\/p>\n<p style=\"text-align: justify;\">13.11.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.11.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.11.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.12. AZD4635: AstraZeneca<\/p>\n<p style=\"text-align: justify;\">13.12.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.12.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.13. Pamiparib (BGB-290): BeiGene<\/p>\n<p style=\"text-align: justify;\">13.13.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.13.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.14. Rubraca (Rucaparib): Clovis Oncology<\/p>\n<p style=\"text-align: justify;\">13.14.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.14.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.14.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.15. Niraparib: Janssen Research &amp; Development<\/p>\n<p style=\"text-align: justify;\">13.15.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.15.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.15.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.16. Proxalutamide (GT0918): Suzhou Kintor Pharmaceutical<\/p>\n<p style=\"text-align: justify;\">13.16.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.16.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.16.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">13.17. Abemaciclib (LY2835219): Eli Lilly and Company<\/p>\n<p style=\"text-align: justify;\">13.17.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.17.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.18. Tomivosertib (eFT508): eFFECTOR Therapeutics<\/p>\n<p style=\"text-align: justify;\">13.18.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.18.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.19. Onvansertib: Trovagene<\/p>\n<p style=\"text-align: justify;\">13.19.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.19.2. Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.19.3. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><strong>14. CRPC: Seven Major Market Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">14.1. Key Findings<\/p>\n<p style=\"text-align: justify;\">14.2. Market Outlook: 7MM<\/p>\n<p style=\"text-align: justify;\"><strong>15. 7MM Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\">15.1. Total Market Size of CRPC in the 7MM<\/p>\n<p style=\"text-align: justify;\">15.2. Total Market size of CRPC by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\">15.3. United States Market Size<\/p>\n<p style=\"text-align: justify;\">15.3.1. Total Market size of CRPC in the United States<\/p>\n<p style=\"text-align: justify;\">15.3.2. Total Market size of CRPC by Therapies in the United States<\/p>\n<p style=\"text-align: justify;\">15.4. EU-5 Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.1. Germany Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.2. France Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.3. Italy Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.4. Spain Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.5. United Kingdom Market Size<\/p>\n<p style=\"text-align: justify;\">15.5. Japan Market Size<\/p>\n<p style=\"text-align: justify;\">15.5.1. Total Market size of CRPC in Japan<\/p>\n<p style=\"text-align: justify;\">15.5.2. Total Market size of CRPC by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><strong>16. Market Access and Reimbursement of CRPC<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. Market Drivers of CRPC<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Market Barriers of CRPC<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\">19.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">19.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>20. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/castrate-resistant-prostate-cancer-market<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market\">Prostate cancer- Market Insight, Epidemiology and Market Forecast -2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030&#8243;<\/strong>&nbsp;report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=castrateresistant-prostate-cancer-crpc-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/castrate-resistant-prostate-cancer-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/castrate-resistant-prostate-cancer-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/castrate-resistant-prostate-cancer-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=castrateresistant-prostate-cancer-crpc-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Castrate-resistant Prostate Cancer (CRPC) -Market Insights, Epidemiology and Market Forecast &#8211; 2030&#8221; DelveInsight has introduced a new&nbsp;Market Insights,&nbsp;Epidemiology, and Market Forecast&nbsp;Report on &#8220;Castrate-Resistant Prostate Cancer &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8220; to its portfolio. &nbsp; DelveInsight&rsquo;s &lsquo;Castrate-resistant Prostate Cancer &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/castrateresistant-prostate-cancer-crpc-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_499061.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,417,406,423,413],"tags":[],"class_list":["post-499061","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499061"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499061\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}